<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161379">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825395</url>
  </required_header>
  <id_info>
    <org_study_id>04-0567</org_study_id>
    <nct_id>NCT01825395</nct_id>
  </id_info>
  <brief_title>Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome</brief_title>
  <acronym>3 4-DAP</acronym>
  <official_title>Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with
      Lambert-Eaton myasthenic syndrome (LEMS).
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">March 2050</completion_date>
  <primary_completion_date type="Anticipated">February 2050</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Lambert Eaton Myasthenic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3, 4-Diaminopyridine</intervention_name>
    <arm_group_label>3, 4-Diaminopyridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 18 years or older, diagnosed with LEMS.

          -  If female, have a negative pregnancy test and, if premenopausal, be willing to
             practice an effective form of birth control during the study.

          -  Tested and found by ECG not to have a prolonged QT syndrome.

          -  Agree to have a second ECG at the time of peak drug effect.

          -  Has understood and signed the Informed Consent

        Exclusion Criteria:

          -  Is known to have a sensitivity to 3, 4-DAP.

          -  Has a history of past or current seizures, cardiac arrhythmia, hepatic, renal or
             hematologic disease or of severe asthma.

          -  Is believed by the investigator to be unable to comply with the protocol.

          -  Is unable to give informed consent.

          -  Is pregnant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven P Ringel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Ales</last_name>
    <phone>6099217447</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Janet Jones</last_name>
      <phone>303-724-2188</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3,4-diaminopyridine</mesh_term>
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
